DDInter1158 DDInter1108
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times . In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated a lower whole-body retention, indicating potentially lower risk for bone marrow toxicity . The presence of a radioligand allows monitoring of treatment response post therapy and prior to next fraction of the dose delivery which may be clinically beneficial in estimating the intensity of lesion uptakes or deciding the dose for subsequent administrations . Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs . Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver . Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared to patients receiving octreotide alone and there was evidence of an overall survival benefit .
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) treats {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) binds {v} (Gene) ALOX5
ALOX5 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) is included by {v} (Pharmacologic Class) Aminosalicylic Acids
Aminosalicylic Acids {u} (Pharmacologic Class) includes {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Lutetium Lu 177 dotatate
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) binds ALOX5 (Gene) and ALOX5 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) binds PPARG (Gene) and PPARG (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) is included by Aminosalicylic Acids (Pharmacologic Class) and Aminosalicylic Acids (Pharmacologic Class) includes Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate